The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study
| dc.authorscopusid | Alper Can / 54884571100 | |
| dc.authorwosid | Alper Can / EPT-7193-2022 | |
| dc.contributor.author | Hizal, Mutlu | |
| dc.contributor.author | Bilgin, Burak | |
| dc.contributor.author | Paksoy, Nail | |
| dc.contributor.author | Açıkgöz, Özgür | |
| dc.contributor.author | Sezer, Ahmet | |
| dc.contributor.author | Can, Alper | |
| dc.date.accessioned | 2021-08-08T08:19:18Z | |
| dc.date.available | 2021-08-08T08:19:18Z | |
| dc.date.issued | 2021 | en_US |
| dc.department | İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.description.abstract | Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after frst-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efcacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 diferent centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3–4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly efective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profle. | en_US |
| dc.identifier.citation | Hizal, M., Bilgin, B., Paksoy, N., Açıkgöz, Ö., Sezer, A., Gürbüz, M., Ak, N., Yücel, Ş., Ayhan, M., Erol, C., Demirkıran, A., Mandel, N. M., Shbair, A., Gökmen, İ., Başoğlu, T., Paydaş, S., Demiray, A. G., İriağaç, Y., Şakalar, T., Zeynelgil, E., … Şendur, M. (2021). The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of cancer research and clinical oncology, 10.1007/s00432-021-03748-7. Advance online publication. https://doi.org/10.1007/s00432-021-03748-7 | en_US |
| dc.identifier.doi | 10.1007/s00432-021-03748-7 | en_US |
| dc.identifier.endpage | 8 | en_US |
| dc.identifier.pmid | 34331582 | en_US |
| dc.identifier.scopus | 2-s2.0-85111543488 | en_US |
| dc.identifier.scopusquality | N/A | en_US |
| dc.identifier.startpage | 1 | en_US |
| dc.identifier.uri | https://doi.org/10.1007/s00432-021-03748-7 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12713/1979 | |
| dc.identifier.wos | WOS:000679766900001 | en_US |
| dc.identifier.wosquality | Q2 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.institutionauthor | Can, Alper | |
| dc.language.iso | en | en_US |
| dc.publisher | Springer | en_US |
| dc.relation.ispartof | Journal of Cancer Research and Clinical Oncology | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Osimertinib | en_US |
| dc.subject | Non-small Cell Lung Cancer | en_US |
| dc.subject | EGFR | en_US |
| dc.subject | T790M | en_US |
| dc.subject | Second Line | en_US |
| dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study | en_US |
| dc.type | Article | en_US |
